Table 5.

Drugs activating the neurogenic detrusor in subject with SCI, reported in the literature over the last two years.

Name	Mechanism of Action	Effect in SCI	Administration Route
Botulinum toxin A [91]		Upper urinary tract protection, modulation of detrusor overactivity and detrusor external sphincter dyssynergia	Injections into detrusor and external urethral sphincter in humans with suprasacral and sacral injuries
Imidafenacin [92]	Anticholinergics selective for the urinary bladder, detrusor pressure reduction and cystometric volume increase	Urodynamic effects with possibly alleviation of bladder complication	Injections in patients with SCI and low cystometric volume and/or detrusor compliance
Inosine [93]	antioxidant by peroxynitrite disattivation, anti-inflammatory, axogenic and neurotrophic properties	Modulation of detrusor overactivity, decrease of non-voiding contraction (NVC), decrease TRPV1 in bladder tissue	Intraperitoneal injection in rat with NVC immediately after SCI
Mirabegron [94]	β-3 agonist	Urodynamic improvement	Administered in patients with neurogenic detrusor overactivity (NDO) after SCI
Naftopidil/BMY7378/Silodosin (α-adrenoceptor blockers) [95]	α-adrenoceptor blockade	Reduction of urethral resistance, voiding efficiency improvement by external urethral sphincter-electromyography(EMG)	Intravenous injection in rat with chronic SCI
Propiverine (antimuscarinic agent) [96]	Antagonism against muscarinic receptor, L-type Ca2+ channels and transient receptor potential vanilloid subtype 1 (TRPV1)	Amelioration of urinary tract dysfunctions and reduction of detrusor overactivity	Administered to rats with SCI and non-voiding contraction (NVC)